Literature DB >> 24183845

Silence Please!: siRNA approaches to tighten the intestinal barrier in vivo.

Kyriaki Bakirtzi1, Jill M Hoffman1, Charalabos Pothoulakis2.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24183845      PMCID： PMC5691337          DOI： 10.1016/j.ajpath.2013.10.001

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  24 in total

1.  Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

Authors:  G D'haens; S Van Deventer; R Van Hogezand; D Chalmers; C Kothe; F Baert; T Braakman; T Schaible; K Geboes; P Rutgeerts
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

2.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

3.  TNF-α modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1.

Authors:  Rana Al-Sadi; Shuhong Guo; Dongmei Ye; Thomas Y Ma
Journal:  Am J Pathol       Date:  2013-10-08       Impact factor: 4.307

4.  Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo.

Authors:  Rana Al-Sadi; Shuhong Guo; Karol Dokladny; Matthew A Smith; Dongmei Ye; Archana Kaza; D Martin Watterson; Thomas Y Ma
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

5.  A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease.

Authors:  R G Shorter; K A Huizenga; R J Spencer
Journal:  Am J Dig Dis       Date:  1972-11

6.  Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR.

Authors:  M Komatsu; D Kobayashi; K Saito; D Furuya; A Yagihashi; H Araake; N Tsuji; S Sakamaki; Y Niitsu; N Watanabe
Journal:  Clin Chem       Date:  2001       Impact factor: 8.327

7.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

Authors:  E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

8.  A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease.

Authors:  Yevgeny Zolotarevsky; Gail Hecht; Athanasia Koutsouris; Deborah E Gonzalez; Cliff Quan; Jeffrey Tom; Randall J Mrsny; Jerrold R Turner
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

9.  Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor.

Authors:  D Hollander; C M Vadheim; E Brettholz; G M Petersen; T Delahunty; J I Rotter
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

10.  Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.

Authors:  Peter Suenaert; Veerle Bulteel; Liesbeth Lemmens; Maja Noman; Benny Geypens; Gert Van Assche; Karel Geboes; Jan L Ceuppens; Paul Rutgeerts
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864
View more
  1 in total

Review 1.  Role of the gastrointestinal ecosystem in the development of type 1 diabetes.

Authors:  Joseph G Daft; Robin G Lorenz
Journal:  Pediatr Diabetes       Date:  2015-05-08       Impact factor: 4.866
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.